Hepion Pharmaceuticals to Participate in the Alliance Global Partners' Virtual Healthcare Symposium

Rhea-AI Summary

Hepion Pharmaceuticals (NASDAQ:HEPA) announced its participation in the Alliance Global Partners' Virtual Healthcare Symposium on November 19, 2020. This event will feature a series of one-on-one meetings with management. The company is focused on developing therapies for liver diseases, particularly non-alcoholic steatohepatitis (NASH). Their lead candidate, CRV431, has shown promise in reducing liver fibrosis and tumor burden in preclinical studies, with potential antiviral effects against HBV, HCV, and HDV.

News Market Reaction – HEPA

+3.73%

+3.73% Session move

In the trading session that priced this news, HEPA gained 3.73%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

EDISON, NJ / ACCESSWIRE / November 17, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("NASH"), today announced that management is scheduled to participate in a series of one-on-one meetings during the Alliance Global Partners' Virtual Healthcare Symposium on November 19, 2020.

Due to the format of the event, no webcast will be available.

About Hepion Pharmaceuticals
Hepion Pharmaceuticals is a clinical stage biopharmaceutical company focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and other types of hepatitis. The Company's lead drug candidate, CRV431, reduces liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH. Preclinical studies also have demonstrated antiviral activities towards HBV, HCV, and HDV through several mechanisms. These diverse therapeutic activities result from CRV431's potent inhibition of cyclophilins, which are involved in many disease processes. Currently in clinical phase development, CRV431 shows potential to play an important role in the overall treatment of liver disease - from triggering events through to end-stage disease.

For further information, please contact:
Stephen Kilmer
Hepion Pharmaceuticals Investor Relations
Direct: (646) 274-3580
skilmer@hepionpharma.com

SOURCE: Hepion Pharmaceuticals, Inc.

View source version on accesswire.com:
https://www.accesswire.com/617185/Hepion-Pharmaceuticals-to-Participate-in-the-Alliance-Global-Partners-Virtual-Healthcare-Symposium

FAQ

What event will Hepion Pharmaceuticals participate in on November 19, 2020?

Hepion Pharmaceuticals will participate in the Alliance Global Partners' Virtual Healthcare Symposium.

What is the focus of Hepion Pharmaceuticals?

Hepion Pharmaceuticals focuses on developing therapies for liver diseases, particularly non-alcoholic steatohepatitis (NASH).

What is the lead drug candidate of Hepion Pharmaceuticals?

The lead drug candidate of Hepion Pharmaceuticals is CRV431, which targets liver fibrosis and hepatocellular carcinoma.

What potential does CRV431 have in treating liver disease?

CRV431 has shown potential to reduce liver fibrosis and tumor burden and has antiviral activities against HBV, HCV, and HDV.